

# Successful Administration of Ipilimumab to Two Kidney Metastatic Melanoma

Journal of Clinical Oncology

32, e69-e71

DOI: 10.1200/jco.2013.49.2314

Citation Report

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Ipilimumab in patients with melanoma and autoimmune disease. , 2014, 2, 35.  |     | 82        |
| 2  | Treatment options for metastatic melanoma in solid organ transplant recipients. JAAD Case Reports, 2015, 1, S26-S28.   | 0.8 | 1         |
| 3  | Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation. , 2015, 3, 22.   |     | 95        |
| 4  | Report of ipilimumab in a heart transplant patient with metastatic melanoma on tacrolimus. Melanoma Management, 2015, 2, 311-314.  | 0.5 | 22        |
| 5  | Structure and Potential Cellular Targets of HAMLET-like Anti-Cancer Compounds made from Milk Components. Journal of Pharmacy and Pharmaceutical Sciences, 2015, 18, 773. | 2.1 | 21        |
| 6  | Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Medicine, 2015, 13, 211.                                  | 5.5 | 570       |
| 7  | Nectin family of cell-adhesion molecules: structural and molecular aspects of function and specificity. Cellular and Molecular Life Sciences, 2015, 72, 645-658.         | 5.4 | 139       |
| 8  | Merkel Cell Carcinoma and Immunosuppression: What We Still Need to Know. Journal of the National Cancer Institute, 2015, 107, dju422-dju422.                             | 6.3 | 15        |
| 9  | Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Annals of Oncology, 2015, 26, 2375-2391.  | 1.2 | 1,136     |
| 10 | Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma. Immunotherapy, 2016, 8, 677-679.   | 2.0 | 7         |
| 11 | Impact of Immune-Modulatory Drugs on Regulatory T Cell. Transplantation, 2016, 100, 2288-2300.   | 1.0 | 99        |
| 12 | Renal Allograft Failure After Ipilimumab Therapy for Metastatic Melanoma: A Case Report and Review of the Literature. Transplantation Proceedings, 2016, 48, 3137-3141.  | 0.6 | 49        |
| 13 | The Bad and the Good News on Cancer Immunotherapy: Implications for Organ Transplant Recipients. Advances in Chronic Kidney Disease, 2016, 23, 312-316.                  | 1.4 | 35        |
| 14 | The Cancer Conundrum. American Journal of Transplantation, 2016, 16, 1041-1042.  | 4.7 | 1         |
| 15 | Tolerability of immune checkpoint inhibition cancer therapy in a cardiac transplant patient. Annals of Oncology, 2016, 27, 2304-2305.                                    | 1.2 | 19        |
| 16 | Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient. European Journal of Cancer, 2016, 67, 66-72.  | 2.8 | 90        |
| 17 | Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities. Clinical Cancer Research, 2016, 22, 4550-4555.  | 7.0 | 73        |
| 18 | Ipilimumab in melanoma. Expert Review of Anticancer Therapy, 2016, 16, 811-826.  | 2.4 | 26        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 19 | Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors. <i>BioDrugs</i> , 2016, 30, 571-584.  | 4.6  | 93        |
| 20 | Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction. , 2016, 4, 60.   |      | 60        |
| 21 | Antitumor activity of nivolumab on hemodialysis after renal allograft rejection. , 2016, 4, 64.   |      | 75        |
| 22 | Daunting but Worthy Goal. <i>Transplantation</i> , 2016, 100, 2569-2583.  | 1.0  | 16        |
| 23 | Current status of alloimmunity. <i>Current Opinion in Nephrology and Hypertension</i> , 2016, 25, 556-562.  | 2.0  | 3         |
| 24 | Management of High-Risk Squamous Cell Carcinoma of the Skin. <i>Current Treatment Options in Oncology</i> , 2016, 17, 34.   | 3.0  | 46        |
| 25 | Management of toxicities of immune checkpoint inhibitors. <i>Cancer Treatment Reviews</i> , 2016, 44, 51-60.  | 7.7  | 706       |
| 26 | Tumor Regression and Allograft Rejection after Administration of Anti-PD-1. <i>New England Journal of Medicine</i> , 2016, 374, 896-898.  | 27.0 | 244       |
| 27 | Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. <i>Annals of Oncology</i> , 2016, 27, 1135-1137.                             | 1.2  | 131       |
| 28 | Renal complications of immune checkpoint blockade. <i>Current Problems in Cancer</i> , 2017, 41, 100-110.   | 2.0  | 81        |
| 29 | Immune checkpoint inhibitors in challenging populations. <i>Cancer</i> , 2017, 123, 1904-1911.  | 4.1  | 266       |
| 30 | Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review. <i>American Journal of Nephrology</i> , 2017, 45, 160-169.   | 3.1  | 10,656    |
| 31 | Keratinocyte Cancer Therapies Enter the Era of Targeted and Immunotherapy. <i>JAMA Dermatology</i> , 2017, 153, 253.  | 4.1  | 0         |
| 32 | Skin Cancers in Organ Transplant Recipients. <i>American Journal of Transplantation</i> , 2017, 17, 2509-2530.  | 4.7  | 151       |
| 33 | Safe Administration of An Anti-PD-1 Antibody to Kidney-transplant Patients: 2 Clinical Cases and Review of the Literature. <i>Journal of Immunotherapy</i> , 2017, 40, 341-344. | 2.4  | 29        |
| 34 | The safety of pembrolizumab in metastatic melanoma and rheumatoid arthritis. <i>Melanoma Research</i> , 2017, 27, 519-523.  | 1.2  | 16        |
| 35 | Challenges faced when identifying patients for combination immunotherapy. <i>Future Oncology</i> , 2017, 13, 1607-1618.   | 2.4  | 10        |
| 36 | Immune Checkpoint Inhibitors in Organ Transplant Patients. <i>Journal of Immunotherapy</i> , 2017, 40, 277-281.   | 2.4  | 120       |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | A review of serious adverse effects under treatment with checkpoint inhibitors. Current Opinion in Oncology, 2017, 29, 136-144.   | 2.4 | 56        |
| 38 | Kidney Toxicities Associated With Novel Cancer Therapies. Advances in Chronic Kidney Disease, 2017, 24, 233-240.  | 1.4 | 14        |
| 39 | Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with hematologic or solid neoplasms: A systematic review. Critical Reviews in Oncology/Hematology, 2017, 120, 86-92.                    | 4.4 | 87        |
| 40 | Immune checkpoints inhibitors for solid tumours after allogeneic haematopoietic stem-cell transplantation: About four clinical cases. European Journal of Cancer, 2017, 81, 138-141.                                    | 2.8 | 1         |
| 41 | Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report. Journal of Medical Case Reports, 2017, 11, 73.                      | 0.8 | 47        |
| 42 | Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma. , 2017, 5, 45.  |     | 20        |
| 43 | Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report. Cancer Immunology, Immunotherapy, 2017, 66, 45-50.   | 4.2 | 55        |
| 44 | Review of high-risk features of cutaneous squamous cell carcinoma and discrepancies between the American Joint Committee on Cancer and NCCN Clinical Practice Guidelines In Oncology. Head and Neck, 2017, 39, 578-594. | 2.0 | 86        |
| 45 | Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer. Oncologist, 2017, 22, 70-80.   | 3.7 | 58        |
| 46 | Anti-PD-1 monotherapy versus anti-PD1 plus anti-CTLA4 in advanced melanoma: how do we decide?. Melanoma Management, 2017, 4, 151-155.   | 0.5 | 2         |
| 47 | Immune Checkpoint Inhibitors in the Cancer Patient with An Organ Transplant. Journal of Onco-Nephrology, 2017, 1, 42-48.  | 0.6 | 21        |
| 48 | Skin Diseases in the Immunosuppressed. , 2018, , .  |     | 2         |
| 49 | Cutaneous Malignancies in Solid Organ Transplant Recipients. , 2018, , 91-116.  |     | 0         |
| 50 | Toxicity profiles of immunotherapy. , 2018, 181, 91-100.  |     | 55        |
| 51 | Cancer immunotherapy in a neglected population: The current use and future of T-cell-mediated checkpoint inhibitors in organ transplant patients. Cancer Treatment Reviews, 2018, 63, 116-121.                          | 7.7 | 37        |
| 52 | Immune checkpoint inhibitor therapy in a liver transplant recipient with a rare subtype of melanoma: a case report and literature review. Melanoma Research, 2018, 28, 61-64.   | 1.2 | 55        |
| 53 | Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience. Journal of Gastrointestinal Oncology, 2018, 9, 1054-1062.                        | 1.4 | 110       |
| 54 | Outcomes of patients with a pretransplant history of early-stage melanoma. Melanoma Research, 2018, 28, 471-474.  | 1.2 | 6         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Checkpoint inhibitor use in two heart transplant patients with metastatic melanoma and review of high-risk populations. <i>Melanoma Management</i> , 2018, 5, MMT10.   | 0.5 | 19        |
| 56 | Immune checkpoint inhibitors in the management of malignancies in transplant recipients. <i>Postgraduate Medical Journal</i> , 2018, 94, 704-708.  | 1.8 | 10        |
| 57 | Liver Allograft Failure After Nivolumab Treatment—A Case Report With Systematic Literature Research. <i>Transplantation Direct</i> , 2018, 4, e376.  | 1.6 | 98        |
| 58 | 12 High-Risk Cutaneous Malignancies. , 2018, , .   |     | 0         |
| 59 | Cancer in kidney transplant recipients. <i>Nature Reviews Nephrology</i> , 2018, 14, 508-520.  | 9.6 | 137       |
| 60 | Graft rejection after immune checkpoint inhibitor therapy in solid organ transplant recipients. <i>Acta Oncologica</i> , 2018, 57, 1414-1418.  | 1.8 | 19        |
| 61 | Immune-checkpoint inhibitors to treat cancers in specific immunocompromised populations: a critical review. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 981-989.  | 2.4 | 11        |
| 62 | Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients. <i>American Journal of Transplantation</i> , 2018, 18, 3065-3071.   | 4.7 | 41        |
| 63 | Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Metastatic Cancer Post Solid Organ Transplantation: A Case Report and Review of the Literature. <i>Transplantation Proceedings</i> , 2019, 51, 3053-3058. | 0.6 | 9         |
| 64 | Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes. <i>Journal of Oncology Practice</i> , 2019, 15, e825-e834.   | 2.5 | 37        |
| 65 | Cancer immunotherapy and its renal effects. <i>Journal of Onco-Nephrology</i> , 2019, 3, 151-159.  | 0.6 | 3         |
| 66 | Programmed Cell Death 1 (PD-1) Inhibitors in Renal Transplant Patients with Advanced Cancer: A Double-Edged Sword?. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2194.                                       | 4.1 | 28        |
| 67 | Report on the 2018 Cancer, Autoimmunity, and Immunology Conference. <i>Journal of Immunology</i> , 2019, 202, 2823-2828.   | 0.8 | 3         |
| 68 | Immunotherapy in organ-transplanted cancer patients: efficacy and risk of organ rejection. <i>Annals of Oncology</i> , 2019, 30, 1173-1177.  | 1.2 | 11        |
| 69 | Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?. <i>Current Opinion in Oncology</i> , 2019, 31, 54-64.   | 2.4 | 66        |
| 70 | Differential Outcomes Among Immunosuppressed Patients With Merkel Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 82-88.  | 1.3 | 39        |
| 71 | Toxicities associated with checkpoint inhibitors—an overview. <i>Rheumatology</i> , 2019, 58, vii7-vii16.  | 1.9 | 80        |
| 72 | Immune Checkpoint Inhibitors and the Risk of Allograft Rejection: A Comprehensive Analysis on an Emerging Issue. <i>Oncologist</i> , 2019, 24, 394-401.  | 3.7 | 48        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | Toxicities in Immune Checkpoint Inhibitors. , 2019, , 205-226.   |     | 2         |
| 74 | Immune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic review. Journal of the American Academy of Dermatology, 2020, 82, 1490-1500.                       | 1.2 | 108       |
| 75 | Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?. Kidney International, 2020, 97, 62-74.   | 5.2 | 121       |
| 76 | Liver transplantation for hepatocellular carcinoma: Management after the transplant. American Journal of Transplantation, 2020, 20, 333-347.   | 4.7 | 88        |
| 77 | Systematic Review of the Safety of Immune Checkpoint Inhibitors Among Kidney Transplant Patients. Kidney International Reports, 2020, 5, 149-158.  | 0.8 | 52        |
| 78 | Poor Outcomes With the Use of Checkpoint Inhibitors in Kidney Transplant Recipients. Transplantation, 2020, 104, 1041-1047.  | 1.0 | 30        |
| 79 | Immuno-oncology for Hepatocellular Carcinoma. Clinics in Liver Disease, 2020, 24, 739-753.   | 2.1 | 8         |
| 81 | Immunotherapy use in kidney transplant recipients: Immune checkpoint inhibitors and CAR-T cell therapy. Journal of Onco-Nephrology, 2020, 4, 165-170.  | 0.6 | 0         |
| 82 | Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma – an update. JDDG - Journal of the German Society of Dermatology, 2020, 18, 582-609.     | 0.8 | 24        |
| 83 | Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events. Kidney International Reports, 2020, 5, 1139-1148.  | 0.8 | 71        |
| 84 | Immune Checkpoint Inhibitor Nephrotoxicity: Update 2020. Kidney360, 2020, 1, 130-140.  | 2.1 | 62        |
| 85 | Cutaneous squamous cell carcinoma in the organ transplant recipient. Oral Oncology, 2020, 103, 104562.   | 1.5 | 19        |
| 86 | Cutaneous squamous cell carcinoma. Memo - Magazine of European Medical Oncology, 2020, 13, 106-110.  | 0.5 | 3         |
| 87 | Successful Treatment of In-Transit Metastatic Melanoma in a Renal Transplant Patient With Combination T-VEC/Imiquimod Immunotherapy. Journal of Immunotherapy, 2020, 43, 149-152.                          | 2.4 | 5         |
| 89 | Intratumoral immunotherapy with anti-PD-1 and TLR9 agonist induces systemic antitumor immunity without accelerating rejection of cardiac allografts. American Journal of Transplantation, 2021, 21, 60-72. | 4.7 | 4         |
| 90 | Cancer immunotherapy in patients with new or recurrent malignancies after liver transplantation. International Journal of Surgery Oncology, 2021, 2, 49.   | 0.2 | 4         |
| 91 | Melanoma en pacientes receptores de un trasplante de Órgano sólido. Actas Dermo-sifiliográficas, 2021, 112, 216-224.   | 0.4 | 3         |
| 92 | Management of Skin Cancers in Solid Organ Transplant Recipients. , 2021, , 267-286.  |     | 0         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 93  | Acute renal transplant rejection following nivolumab therapy for metastatic melanoma. BMJ Case Reports, 2021, 14, e238037.   | 0.5 | 9         |
| 94  | Melanoma in Solid Organ Transplant Recipients. Actas Dermo-sifiliográficas, 2021, 112, 216-224.  | 0.4 | 2         |
| 95  | Cutaneous Head and Neck Cancers in the High-Risk Immunosuppressed Population. Otolaryngologic Clinics of North America, 2021, 54, 397-413.   | 1.1 | 0         |
| 96  | Skin Cancers and Lung Transplant. Seminars in Respiratory and Critical Care Medicine, 2021, 42, 483-496.   | 2.1 | 1         |
| 97  | Application of Immune Checkpoint Inhibitors in Solid Organ Transplantation Recipients: A Systematic Review. Interdisciplinary Sciences, Computational Life Sciences, 2021, 13, 801-814.                | 3.6 | 7         |
| 98  | High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: A Clinical Review. Annals of Surgical Oncology, 2021, 28, 9009-9030.   | 1.5 | 7         |
| 99  | T-cell Exhaustion in Organ Transplantation. Transplantation, 2022, 106, 489-499.   | 1.0 | 14        |
| 100 | Management of the kidney transplant patient with Cancer: Report from a Multidisciplinary Consensus Conference. Transplantation Reviews, 2021, 35, 100636.  | 2.9 | 4         |
| 101 | A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. Kidney International, 2021, 100, 196-205.                                       | 5.2 | 95        |
| 102 | Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation. Cancers, 2021, 13, 4882.  | 3.7 | 15        |
| 103 | Malignancy Following Lung Transplantation. , 2022, , 764-777.  |     | 0         |
| 104 | Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade. JAAD Case Reports, 2017, 3, 412-415. | 0.8 | 40        |
| 105 | Management of checkpoint inhibitor-associated renal toxicities. Expert Review of Quality of Life in Cancer Care, 2017, 2, 215-223.   | 0.6 | 6         |
| 106 | Immune Checkpoint Inhibitors in Transplantation—A Case Series and Comprehensive Review of Current Knowledge. Transplantation, 2021, 105, 67-78.  | 1.0 | 21        |
| 107 | Prospects for personalized targeted therapies for cutaneous squamous cell carcinoma. Seminars in Cutaneous Medicine and Surgery, 2014, 33, 72-75.  | 1.6 | 11        |
| 108 | The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature. Oncologist, 2020, 25, 505-514.   | 3.7 | 93        |
| 109 | PLK1 Inhibition alleviates transplant-associated obliterative bronchiolitis by suppressing myofibroblast differentiation. Aging, 2020, 12, 11636-11652.  | 3.1 | 8         |
| 110 | Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 255-289.         | 4.9 | 393       |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 111 | High-risk Cutaneous Squamous Cell Carcinoma. International Journal of Head and Neck Surgery, 2017, 8, 37-44.  | 0.2 | 1         |
| 112 | Immune Checkpoint Inhibitors in Patients with Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Case Report and Literature Review. Current Cancer Drug Targets, 2020, 20, 720-727.                    | 1.6 | 12        |
| 113 | Renal Toxicity. Advances in Experimental Medicine and Biology, 2020, 1244, 287-293.   | 1.6 | 0         |
| 114 | Immune-checkpoint inhibitors in renal transplanted patients affected by melanoma: a systematic review. Immunotherapy, 2022, 14, 65-75.  | 2.0 | 6         |
| 115 | Renal Toxicity. Advances in Experimental Medicine and Biology, 2021, 1342, 389-397.   | 1.6 | 0         |
| 116 | Biological therapies in patients with liver disease: are they really lifesavers?. Expert Opinion on Biological Therapy, 2022, 22, 473-490.  | 3.1 | 0         |
| 118 | Emerging Concepts in Managing Malignancy in Kidney Transplant Patients. Seminars in Nephrology, 2022, 42, 63-75.  | 1.6 | 4         |
| 119 | Efficient multiple treatments including molecular targeting agents in a case of recurrent hepatocellular carcinoma, post-living donor liver transplantation. Clinical Journal of Gastroenterology, 2022, 15, 755-764. | 0.8 | 3         |
| 120 | Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates. Korean Journal of Transplantation, 2022, 36, 82-98.   | 0.1 | 9         |
| 121 | Transplant Onconephrology in Patients With Kidney Transplants. Advances in Chronic Kidney Disease, 2022, 29, 188-200.e1.  | 1.4 | 4         |
| 122 | Nephrology (Kidney). , 2022, , 197-214.   |     | 0         |
| 123 | Therapeutic strategies for post-transplant recurrence of hepatocellular carcinoma. World Journal of Gastroenterology, 2022, 28, 4929-4942.  | 3.3 | 5         |
| 124 | Immune checkpoint blockade for organ-transplant recipients with cancer: A review. European Journal of Cancer, 2022, 175, 326-335.   | 2.8 | 8         |
| 126 | Immune checkpoint inhibitor induced nephrotoxicity: An ongoing challenge. Frontiers in Medicine, 0, 9, .  | 2.6 | 1         |
| 128 | Allograft rejection following immune checkpoint inhibitors in solid organ transplant recipients: A safety analysis from a literature review and a pharmacovigilance system. Cancer Medicine, 2023, 12, 5181-5194.     | 2.8 | 3         |
| 129 | Postoperative adjuvant therapy for hepatocellular carcinoma with microvascular invasion. World Journal of Gastrointestinal Surgery, 0, 15, 19-31.   | 1.5 | 4         |
| 130 | Immune checkpoint inhibitors in kidney transplantation. Current Opinion in Organ Transplantation, 2023, 28, 46-54.  | 1.6 | 4         |
| 131 | A Review of the Pharmacokinetic Characteristics of Immune Checkpoint Inhibitors and Their Clinical Impact Factors. Pharmacogenomics and Personalized Medicine, 0, Volume 16, 29-36.                                   | 0.7 | 0         |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 132 | European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatmentâ€“Update 2023. European Journal of Cancer, 2023, 193, 113252.                     | 2.8 | 5         |
| 134 | Programmed cell death ligand 1 expression associated with subtypes of postâ€“transplant lymphoproliferative disorder among pediatric kidney transplant recipients. Clinical Transplantation, 2023, 37, . | 1.6 | 1         |
| 135 | Adverse renal effects of check-point inhibitors (ICI) in cancer patients: Recommendations of the Onco-nephrology Working Group of the Spanish Society of Nephrology. Nefrologia, 2023, 43, 622-635.      | 0.4 | 0         |
| 136 | Use of immune checkpoint inhibitors in solid organ transplant recipients with advanced cutaneous malignancies. , 0, 2, .   |     | 0         |
| 137 | Metastatic Melanoma Treatment in Special Populations. Cancer Journal (Sudbury, Mass ), 2024, 30, 71-78.  | 2.0 | 0         |